Literature DB >> 1289353

Growth-rate-independent killing by ciprofloxacin of biofilm-derived Staphylococcus epidermidis; evidence for cell-cycle dependency.

I G Duguid1, E Evans, M R Brown, P Gilbert.   

Abstract

Cell culture methods that allow culture of Staphylococcus epidermidis biofilms at controlled growth rates were used to examine susceptibility to ciprofloxacin. Changes in biofilm susceptibility, dependent upon growth rate, were compared with those for suspended populations grown in chemostat, and also for newly-formed daughter cells shed from the biofilm during its growth and development. Susceptibility increased for intact and resuspended biofilms, and also for planktonic cultures, with increases in growth rate. The dependence of susceptibility upon growth rate was greatest for slow growing cells (mu, 0.01-0.15/h). At any particular growth rate, biofilms appeared more susceptible than their planktonic counterparts. Newly-formed daughter cells were relatively tolerant to ciprofloxacin at all rates of growth. Lack of growth rate dependency for the newly-formed cells suggested a role for the cell-division cycle in determining resistance. This was confirmed by examining the susceptibility of S. epidermidis throughout batch cultures with cell division synchronized. Perfusion of various steady-state biofilms with ciprofloxacin demonstrated killing of the adherent population even at much reduced rates of growth.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1289353     DOI: 10.1093/jac/30.6.791

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  23 in total

1.  The relative contributions of physical structure and cell density to the antibiotic susceptibility of bacteria in biofilms.

Authors:  Amy E Kirby; Kimberly Garner; Bruce R Levin
Journal:  Antimicrob Agents Chemother       Date:  2012-03-26       Impact factor: 5.191

2.  Lytic activity of recombinant bacteriophage phi11 and phi12 endolysins on whole cells and biofilms of Staphylococcus aureus.

Authors:  Peter Sass; Gabriele Bierbaum
Journal:  Appl Environ Microbiol       Date:  2006-11-03       Impact factor: 4.792

3.  Evaluation of Fleroxacin Activity against Established Pseudomonas fluorescens Biofilms.

Authors:  D R Korber; G A James; J W Costerton
Journal:  Appl Environ Microbiol       Date:  1994-05       Impact factor: 4.792

4.  Hyperosmotic Agents and Antibiotics Affect Dissolved Oxygen and pH Concentration Gradients in Staphylococcus aureus Biofilms.

Authors:  Mia Mae Kiamco; Erhan Atci; Abdelrhman Mohamed; Douglas R Call; Haluk Beyenal
Journal:  Appl Environ Microbiol       Date:  2017-03-02       Impact factor: 4.792

5.  Role of antibiotic penetration limitation in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin.

Authors:  J N Anderl; M J Franklin; P S Stewart
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

6.  Modification by surface association of antimicrobial susceptibility of bacterial populations.

Authors:  D G Allison; P Gilbert
Journal:  J Ind Microbiol       Date:  1995-10

Review 7.  Staphylococcus epidermidis--the 'accidental' pathogen.

Authors:  Michael Otto
Journal:  Nat Rev Microbiol       Date:  2009-08       Impact factor: 60.633

Review 8.  Implantable Device-Related Infection.

Authors:  J Scott VanEpps; John G Younger
Journal:  Shock       Date:  2016-12       Impact factor: 3.454

9.  Linezolid compared with eperezolid, vancomycin, and gentamicin in an in vitro model of antimicrobial lock therapy for Staphylococcus epidermidis central venous catheter-related biofilm infections.

Authors:  John Curtin; Martin Cormican; Gerard Fleming; John Keelehan; Emer Colleran
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

10.  Effect of growth rate on resistance of Candida albicans biofilms to antifungal agents.

Authors:  G S Baillie; L J Douglas
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.